Jump to content

Lindane: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Undid revision 336539541 by Blancer707 (talk) per talk. Too much detail for the infobox. US status is covered in the article.
trim the fat from LEAD. Everything removed from LEAD is still discussed in BODY of the article.
Line 33: Line 33:
'''Lindane''', also known as '''''gamma''-hexachlorocyclohexane''', (γ-HCH), '''gammaxene''', '''Gammallin''' and erroneously known as '''[[benzene hexachloride]]''' (BHC),<ref name="bhc-misnomer">{{cite book |title= Analytical toxicology: for clinical, forensic, and pharmaceutical chemists |last1= Brandenberger |first1= Hans |last2= Maes |first2= Robert A. A. |year= 1997 |publisher= Walter de Gruyter |location= Berlin |isbn= 9783110107319 |page= 243 |url= http://books.google.co.uk/books?id=ZhYtynyC4kAC&pg=PA243&lpg=PA243 |accessdate= 2009-05-10}}</ref> is an [[organochlorine]] chemical variant of [[hexachlorocyclohexane]] that has been used both as an agricultural [[insecticide]] and as a [[pharmaceutical]] treatment for infestations of [[Pediculosis|lice]] and [[scabies]].<ref name="drugs.com">[http://www.drugs.com/mmx/lindane.html Drugs.com Professional Drug Information: Lindane]. Retrieved 2009-05-10</ref><ref name="x4"> Commission for Environmental Cooperation. The North American Regional Action Plan (NARAP) on Lindane and Other Hexachlorocyclohexane (HCH) Isomers. 2005. Available at: http://www.cec.org/files/PDF/POLLUTANTS/Lindane-NARAP-Public-Comment_en.pdf.</ref>
'''Lindane''', also known as '''''gamma''-hexachlorocyclohexane''', (γ-HCH), '''gammaxene''', '''Gammallin''' and erroneously known as '''[[benzene hexachloride]]''' (BHC),<ref name="bhc-misnomer">{{cite book |title= Analytical toxicology: for clinical, forensic, and pharmaceutical chemists |last1= Brandenberger |first1= Hans |last2= Maes |first2= Robert A. A. |year= 1997 |publisher= Walter de Gruyter |location= Berlin |isbn= 9783110107319 |page= 243 |url= http://books.google.co.uk/books?id=ZhYtynyC4kAC&pg=PA243&lpg=PA243 |accessdate= 2009-05-10}}</ref> is an [[organochlorine]] chemical variant of [[hexachlorocyclohexane]] that has been used both as an agricultural [[insecticide]] and as a [[pharmaceutical]] treatment for infestations of [[Pediculosis|lice]] and [[scabies]].<ref name="drugs.com">[http://www.drugs.com/mmx/lindane.html Drugs.com Professional Drug Information: Lindane]. Retrieved 2009-05-10</ref><ref name="x4"> Commission for Environmental Cooperation. The North American Regional Action Plan (NARAP) on Lindane and Other Hexachlorocyclohexane (HCH) Isomers. 2005. Available at: http://www.cec.org/files/PDF/POLLUTANTS/Lindane-NARAP-Public-Comment_en.pdf.</ref>


Lindane works as a [[neurotoxin]] by interfering with [[GABA]] [[neurotransmitter]] function, specifically by interacting with the [[GABAA receptor|GABA<sub>A</sub> receptor]]-chloride channel complex at the [[picrotoxin]] binding site. In humans, exposure to toxic amounts of lindane primarily affects the [[nervous system]].<ref name="Agency">Agency for Toxic Substances and Disease Registry, U.S. Department of Health and Human Services. Toxicologic profile for alpha-, beta, gamma- and delta-hexachlorocyclohenxane. August 2005. http://www.atsdr.cdc.gov/toxprofiles/tp43.pdf</ref><ref name="VolRED">[http://www.epa.gov/oppsrrd1/REDs/factsheets/lindane_fs_addendum.htm Lindane Voluntary Cancellation and RED Addendum Fact Sheet], US EPA, July name 2006.</ref> Limited data suggest that lindane may be an endocrine disruptor but additional research is needed to determine the relevance to public health. Data regarding carcinogenicity have been conflicting, though the most recent assessments indicate that lindane is not likely to pose a major cancer risk to humans.<ref name="IARC"> International Agency for Research on Cancer (IARC). Summaries & Evaluations: HEXACHLOROCYCLOHEXANES (Group 2B). Updated March 2, 1998. http://www.inchem.org/documents/iarc/suppl7/hexachlorocyclohexanes.html</ref><ref name="EPACA"> U.S. EPA. Evaluation of the Carcinogenic Potential of Lindane, PC. Code: 009001. 2001. http://www.lindane.com/pdf/EPA_Cancer_Assessment_of_Lindane2001.pdf</ref><ref name="WhoH2O"> World Health Organization (WHO). Lindane in Drinking Water: Background Document for Development of WHO Guidelines for Drinking-Water Quality. 2004.</ref>
Lindane a [[neurotoxin]] with [[GABA]] [[neurotransmitter]] function by interacting with the [[GABAA receptor|GABA<sub>A</sub> receptor]]-chloride channel complex at the [[picrotoxin]] binding site. In humans, lindane affects the [[nervous system]].<ref name="Agency">Agency for Toxic Substances and Disease Registry, U.S. Department of Health and Human Services. Toxicologic profile for alpha-, beta, gamma- and delta-hexachlorocyclohenxane. August 2005. http://www.atsdr.cdc.gov/toxprofiles/tp43.pdf</ref><ref name="VolRED">[http://www.epa.gov/oppsrrd1/REDs/factsheets/lindane_fs_addendum.htm Lindane Voluntary Cancellation and RED Addendum Fact Sheet], US EPA, July name 2006.</ref> lindane an endocrine disruptor.<ref name="IARC"> International Agency for Research on Cancer (IARC). Summaries & Evaluations: HEXACHLOROCYCLOHEXANES (Group 2B). Updated March 2, 1998. http://www.inchem.org/documents/iarc/suppl7/hexachlorocyclohexanes.html</ref><ref name="EPACA"> U.S. EPA. Evaluation of the Carcinogenic Potential of Lindane, PC. Code: 009001. 2001. http://www.lindane.com/pdf/EPA_Cancer_Assessment_of_Lindane2001.pdf</ref><ref name="WhoH2O"> World Health Organization (WHO). Lindane in Drinking Water: Background Document for Development of WHO Guidelines for Drinking-Water Quality. 2004.</ref>


The [[World Health Organization]] classifies lindane as "Moderately Hazardous," based on acute animal toxicity studies and its international trade is restricted and regulated under the [[Rotterdam Convention]] on Prior Informed Consent.<ref name="WHOClass">World Health Organization, [http://www.who.int/ipcs/publications/pesticides_hazard_rev_3.pdf ''The WHO Recommended Classification of Pesticides by Hazard''], 2005.</ref> It is presently banned in more than 50 countries, and in 2009 was included in the [[Stockholm Convention]] on [[persistent organic pollutants]], which bans its production and use for agricultural purposes in participating (ratified) countries but with a specific exemption for use as a human health pharmaceutical for the control of head lice and scabies as second-line treatment. <ref name="engeler">Eliane Engeler, "UN: Treaty expanded by 9 more dangerous chemicals", Associated Press 2009-05-09</ref> While the US is not currently a member country to the Stockholm Convention, it similarly called for the voluntary cancellation of registered agricultural products but continues to support FDA-approved medical uses of pharmaceutical lindane.
The [[World Health Organization]] classifies lindane as "Moderately Hazardous," and its international trade is restricted and regulated under the [[Rotterdam Convention]] on Prior Informed Consent.<ref name="WHOClass">World Health Organization, [http://www.who.int/ipcs/publications/pesticides_hazard_rev_3.pdf ''The WHO Recommended Classification of Pesticides by Hazard''], 2005.</ref> was the [[Stockholm Convention]] on [[persistent organic pollutants]] as a pharmaceutical for lice and scabies. <ref name="engeler">Eliane Engeler, "UN: Treaty expanded by 9 more dangerous chemicals", Associated Press 2009-05-09</ref>


==History==
==History==

Revision as of 18:51, 9 January 2010

Lindane
Clinical data
Pregnancy
category
  • C
Routes of
administration		Topical
ATC code
Legal status
Legal status
  • US: WARNING[1]
  • In 2009, the Stockholm Convention banned agricultural uses globally in 166 countries, but permitted pharmaceutical use for 5 more years.[2]
Pharmacokinetic data
Protein binding91%
MetabolismHepatic cytochrome P-450 oxygenase system
Elimination half-life18 hours
Identifiers
  • (1r,2R,3S,4r,5R,6S)-1,2,3,4,5,6-hexachlorocyclohexane
CAS Number
PubChem CID
DrugBank
ChemSpider
CompTox Dashboard (EPA)
ECHA InfoCard100.000.365 Edit this at Wikidata
Chemical and physical data
FormulaC6H6Cl6
Molar mass290.83 g/mol g·mol−1
3D model (JSmol)
  • Cl[C@H]1[C@H](Cl)[C@H](Cl)[C@@H](Cl)[C@H](Cl)[C@@H]1Cl
  (verify)

Lindane, also known as gamma-hexachlorocyclohexane, (γ-HCH), gammaxene, Gammallin and erroneously known as benzene hexachloride (BHC),[3] is an organochlorine chemical variant of hexachlorocyclohexane that has been used both as an agricultural insecticide and as a pharmaceutical treatment for infestations of lice and scabies.[4][5]

Lindane is a neurotoxin that interferes with GABA neurotransmitter function by interacting with the GABAA receptor-chloride channel complex at the picrotoxin binding site. In humans, lindane affects the nervous system, liver and kidneys, and may be a carcinogen.[6][7] It is unclear whether lindane is an endocrine disruptor.[8][9][10]

The World Health Organization classifies lindane as "Moderately Hazardous," and its international trade is restricted and regulated under the Rotterdam Convention on Prior Informed Consent.[11] In 2009 the production and agricultural use of lindane was banned under the Stockholm Convention on persistent organic pollutants. A specific exemption to that ban allows it to continue to be used as a second-line pharmaceutical treatment for lice and scabies. [12]

History

In the United States, lindane pesticide products are regulated by the U.S. Environmental Protection Agency (EPA), while lindane-based medications are regulated by the Food and Drug Administration (FDA). In the 1940s, lindane was registered as an agricultural insecticide, and in 1951 it was approved for medical use in the treatment of scabies and lice. Since this time, the vast majority of lindane use -- more than 99% -- has been in agriculture and much of the safety and environmental concerns have related to this application.[13][14] In 2006, the EPA called for the voluntary cancellation of all agricultural uses of lindane, which in recent years had already been limited to pre-planting seed treatments.[15] Lindane medications continue to be available in the US,[16] and Canada and other countries have similarly banned agricultural use while allowing its use in medicine to continue. Notably, lindane-based agricultural products generally contain much higher concentrations of lindane compared with pharmaceutical treatments, often in combination with other agricultural chemicals.[17]

Lindane medications

Lindane is a prescription topical treatment for head lice and scabies, and it is formulated as a shampoo and a lotion. Since 1995 it has been designated a "second-line" treatment, meaning it should be used only when other "first-line" treatments with more favorable risk profiles have failed, cannot be tolerated or are otherwise contraindicated.[16][18][19][20]

Resistance to lindane and other agents used to treat scabies and lice has been reported in the US and elsewhere, and is an important cause of treatment failure in areas where resistance has emerged. [21][22][23][24][25][26][27][28][29][30][31] The actual rate of clinical resistance to lindane and other scabicides and pediculicides in the US is not known but varies geographically.[32]Moreover, because there are no recent controlled clinical studies evaluating the efficacy of lindane versus other approved treatments in the US, it is not known how lindane would compare with these agents today. Resistance to permethrin, in particular, is a growing concern because of its extensive use and availability as an over-the-counter first-line treatment. [33][34] To this point, the most recent authoritative review of head lice treatments by international experts ("The Cochrane Review") was withdrawn in 2007 for lack of direct contemporary evidence of the comparative effectiveness of head lice treatments, noting that " The 'best' choice will now depend on local resistance patterns."[35]

In December 2007, the FDA sent a warning letter to Morton Grove Pharmaceuticals, the sole U.S. manufacturer of lindane products,[36] requesting that the company correct misleading advertising information contained in two websites developed by Alliant Pharmaceuticals. The letter said, in part, that the materials "are misleading in that they omit and/or minimize the most serious and important risk information associated with the use of Lindane Shampoo, particularly in pediatric patients; include a misleading dosing claim; and overstate the efficacy of Lindane Shampoo."[37] Morton Grove responded with corrective actions and the contract with Alliant Pharmaceuticals terminated in May 2007.[38]

The State of California banned the pharmaceutical use of lindane, effective 2002. The Michigan House of Representatives passed House Bill 4402 in March 2009 to restrict the use of pharmaceutical lindane to doctors' offices. [39] A recent analysis[40] of the California ban found that 78% of 135 pediatricians responding to a mail-in survey had not experienced problems treating lice or scabies since that ban took effect. By contrast, 22% expressed difficulty in managing these infections, which they most often attributed to the development of resistance. The authors noted that calls to the California Poison Control System relating to lindane exposure had already been declining gradually in the years prior to the ban (1998-2002) but went to near zero after the ban took effect (2004-2006). No comparative data from poison control centers in other states were provided as part of the California analysis. [40]

The study also documented a decrease in the amount of lindane in California wastewater entering water treatment plants. The level of lindane in purified water discharged from California water treatment works was not measured in this study, nor was lindane assessed in sources of California drinking water. [40] Nonetheless, it was in the authors’ opinion that the "California experience" suggests that elimination of pharmaceutical lindane reduced reported unintentional exposures, did not adversely affect head lice and scabies treatment and produced environmental benefits. [40]

In 2002, however, the US Environmental Protection Agency (EPA) concluded to the contrary that the amount of lindane in public water supplies resulting from the use of lindane-based medications was "extremely low" and not of concern. [14] (See also Environmental Contamination)

Human health effects

The EPA and WHO both classify lindane as "moderately" acutely toxic. It has an oral LD50 of 88 mg/kg in rats and a dermal LD50 of 1000 mg/kg. Most of the adverse human health effects reported for lindane have been related to agricultural uses and chronic, occupational exposure of seed treatment workers.[41]

Exposure to large amounts of lindane can harm the nervous system, producing a range of symptoms from headache and dizziness to seizures, convulsions and more rarely death.[6][42] The most common side effects associated with the use of lindane medications are burning sensations, itching, dryness and rash.[43]Lindane has not been shown to affect the immune system in humans and, it is not considered to be genotoxic.[6] Prenatal exposure to β-HCH, an isomer of hexachlorocyclohexane and production byproduct, has been associated with altered thyroid hormone levels and could affect brain development.[44] Prior to 1974, technical-grade HCH—a mixture of HCH isomers including the β form—was used agriculturally in the US.

Cancer risk

Assessments of the carcinogenicity of lindane have been conflicting, though more recent authoritative reviews of the available data have found that lindane is not likely to pose a major cancer risk to humans. In 2004, the Joint Commission of Pesticide Residues (JMPR) of the World Health Organization (WHO) and Food Agricultural Organization (FAO) of the United Nations concluded that "lindane is not likely to pose a carcinogenic risk to humans" based on the weight of scientific evidence from carcinogenicity studies. [10] In 2001, the Cancer Assessment Review Committee of the EPA issued a report on lindane in which they found "major deficiencies" with many of the experimental animal studies that had been conducted previously, prompting additional research and subsequent reclassification of lindane from "possibly carcinogenic" into the lesser category of "Suggestive evidence of carcinogenicity, but not sufficient to assess human carcinogenic potential." The expert Committee further recommended that additional assessment of cancer risk in humans was not necessary.[9]

In 1987, the International Agency for Research on Cancer (IARC) classified the broader chemical class of hexachlorocyclohexanes (HCH) that lindane belongs to as group 2B "possible" human carcinogens, with the caveat that human evidence relating specifically to lindane was inadequate and that findings from animal cancer studies were equally limited.[8] Likewise, the U.S. Department of Health and Human Services determined that hexachlorocyclohexanes, including lindane, "may reasonably be anticipated to cause cancer in humans" based on earlier experimental animal studies reported by the IARC (1979, 1982, 1987) and the National Cancer Institute (1977), but similarly noting that "evidence for carcinogenicity in humans was inadequate."[6] [8][45]

Adverse reactions to lindane pharmaceuticals

A variety of adverse reactions to lindane pharmaceuticals have been reported, though the most common are nonserious reactions of the skin. [46][47][48] However, systemic effects have been reported, including dizziness and headache and in rare instances seizures, and even more rarely death. [49] While rare serious effects have most often resulted from misuse, such as oral ingestions and excessive applications, adverse reactions have occurred when used properly.[50][51][16][49] The FDA therefore requires a so-called black box warning on lindane products, which explains the risks of lindane products and their proper use.[4] [52] Likewise, the FDA limited lindane medications to small 2 oz. bottles to minimize the risk of product misuse and accidental poisoning.[20]

The black box warning emphasizes that lindane should not be used on premature infants and individuals with known uncontrolled seizure disorders, and should be used with caution in infants, children, the elderly, and individuals with other skin conditions (e.g., dermatitis, psoriasis) and people who weigh less than 110 lbs (50 kg) as they may be at risk of serious neurotoxicity. [50][51]

Environmental contamination

Lindane is a persistent organic pollutant: it is relatively long-lived in the environment, it is transported long distances by natural processes like global distillation, and it can bioaccumulate in food chains, though it is rapidly eliminated when exposure is discontinued.[41]

The production and agricultural use of lindane are the primary causes of environmental contamination,[53] and levels of lindane in the environment have been decreasing in the U.S., consistent with decreasing agricultural usage patterns.[54] The production of lindane generates large amounts of waste hexachlorocyclohexane isomers, and it is estimated that "every ton of lindane manufactured produces about 9 tons of toxic waste."[55] Modern manufacturing standards for lindane involve the treatment and conversion of waste isomers to less toxic molecules, a process known as "cracking." [54] [56]

When lindane is used in agriculture, an estimated 12-30% of it volatilizes into the atmosphere, where it is subject to long-range transport and can be deposited by rainfall. Lindane in soil can leach to surface and even ground water and can bioaccumulate in the food chain. [15] However, biotransformation and elimination are relatively rapid when exposure is discontinued. [13] Most exposure of the general population to lindane has resulted from agricultural uses and the intake of foods, such as produce, meats and milk, produced from treated agricultural commodities. Human exposure has decreased significantly since the cancellation of agricultural uses in 2006. Even so, the CDC published in 2005 its Third National Report on Human Exposures to Environmental Chemicals, which found no detectable amounts of lindane in human blood taken from a random sampling of about 5,000 people in the US as part of the NHANES study (National Health and Nutrition Examination Survey at: http://www.cdc.gov/nchs/nhanes/about_nhanes.htm ).[57] The lack of detection of lindane in this large human "biomonitoring" study likely reflects the increasingly limited agricultural uses of lindane over the last two decades. The cancellation of agricultural uses in the U.S. will further reduce the amount of lindane introduced into the environment by more than 99%. [15][13]

Over time, lindane is broken down in soil, sediment and water into less harmful substances by algae, fungi and bacteria; however, the process is relatively slow and dependent on ambient environmental conditions.[6] The ecological impact of lindane’s environmental persistence continues to be debated.

The US EPA determined in 2002 that the Agency does not believe that lindane contaminates drinking water in excess of levels considered safe.[6] U.S. Geologic Survey teams concluded the same in 1999 and 2000.[58] With regard to lindane medications, the EPA conducted "down-the-drain" estimates of the amount of lindane reaching public water supplies and concluded that lindane levels from pharmaceutical sources were "extremely low" and not of concern.[14]

Note that the EPA has set the maximum contaminant level or "MCL" for lindane allowed in public water supplies and considered safe for drinking at 200 parts per trillion (ppt).[59] By comparison, the state of California imposes a lower MCL for lindane of 19 ppt.[40] However, the California standard is based on a dated 1988 national water criterion that was subsequently revised by the EPA in 2003 to 980 ppt. [9][60][61][59] The EPA stated that the change resulted from "significant scientific advances made in the last two decades particularly in the areas of cancer and noncancer risk assessments." [59] While the EPA considered raising the MCL standard for lindane to 980 ppt at that time, the change was never implemented because states had little difficultly in maintaining lindane levels below the 200 ppt MCL limit already in place. [59] Today, the legally enforceable MCL standard for lindane is 200 ppt while the national water criterion for lindane is 980 ppt. [59]

Isomers

Lindane is the gamma isomer of hexachlorocyclohexane ("γ-HCH"). In addition to the issue of lindane pollution are concerns related to the other isomers of HCH, namely alpha-HCH and beta-HCH, which are notably more toxic than lindane, lack its insecticidal properties, and are byproducts of lindane production.[6] In the 1940s and 1950s lindane producers stockpiled these isomers in open heaps, which led to ground and water contamination. The International HCH and Pesticide Forum has since been established to bring together experts to address the clean-up and containment of these sites.[56][dead link] Modern manufacturing standards for lindane involve the treatment and conversion of waste isomers to less toxic industrial chemicals, a process known as "cracking."[6][56] Today, only a few production plants remain active worldwide to accommodate public health uses of lindane and declining agricultural needs.[13] Lindane has not been manufactured in the U.S. since the mid-1970s but continues to be imported.

  • α-hexachlorocyclohexane
    α-hexachlorocyclohexane
  • β-hexachlorocyclohexane
    β-hexachlorocyclohexane

Regulatory status

As of November 2006, Lindane was banned in 52 countries, restricted in 33 countries, not registered in 10 countries, and registered in 17 countries.[13][53] The latter includes the U.S. and Canada, which support public health uses of pharmaceutical lindane but no longer allow agricultural applications. [15][13] In May 2009, lindane (as well as the alpha- and beta-isomers of hexachlorocyclohexane) was listed in Annex A of the Stockholm Convention On Persistent Organic Pollutants, which bans agricultural uses of lindane in ratified countries, with a specific exemption for use of lindane as a human health pharmaceutical for the control of head lice and scabies as second-line treatment. [62] Although the US is not a member country to the Stockholm Convention, it has similarly abandoned agricultural uses of lindane while supporting approved public health applications. [62][12][63][64] Lindane is still used in agriculture in India,[65] Nigeria,[66] and elsewhere.

Lindane is banned in California, and there are currently bills pending in the New York and Michigan state legislatures that would further restrict its medical uses on children in the those states.[67][68] The Michigan bill which would require use of lindane in physician offices only, passed the House on May 2008, and again in March, 2009 but has not passed the Senate. [69]

Morton Grove lawsuit

In the face of negative publicity concerning its lindane products, in 2006 Morton Grove Pharmaceuticals filed a lawsuit against the National Pediculosis Association, the Michigan Ecology Center, and two physicians, alleging that statements they disseminated to healthcare providers and consumers constituted defamation, tortious interference, trade disparagement, and deceptive trade practices. Morton Grove alleged more than $9.3 million in damages. The case pled that "[d]efendants swap agricultural and pharmaceutical research selectively quoting and/or misstating findings from studies relating to the agricultural use of lindane, and widely disseminate false, misleading, and defamatory statements about the safety profile and effectiveness of lindane."[70] The defendants considered the legal action to be SLAPP suit.

Morton Grove and the Ecology Center settled in 2008. The settlement did not require the defendants to admit liability or make any payments to Morton Grove, but the Ecology Center did agree to clarify 7 of the statements it had published in its lindane factsheet.[68][71][72] Morton Grove re-filed its complaint against the National Pediculosis Association, seeking a permanent injunction and corrective advertising under the Lanham Act and companion Illinois' statutes. This case remains ongoing.[73] [verification needed]

Morton Grove Pharmaceuticals and the National Pediculosis Association have agreed to dismiss their respective lawsuits with no admission of wrongdoing and no payment of any damages.

See also

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ Report of the Conference of the Parties of the Stockholm Convention on Persistent Organic Pollutants on the work of its fourth meeting. Convention on Persistent Organic Pollutants. Fourth meeting, Geneva, 4–8 May 2009. http://chm.pops.int/Portals/0/Repository/COP4/UNEP-POPS-COP.4-38.English.pdf
  3. ^ Brandenberger, Hans; Maes, Robert A. A. (1997). Analytical toxicology: for clinical, forensic, and pharmaceutical chemists. Berlin: Walter de Gruyter. p. 243. ISBN 9783110107319. Retrieved 2009-05-10.
  4. ^ a b Drugs.com Professional Drug Information: Lindane. Retrieved 2009-05-10
  5. ^ Commission for Environmental Cooperation. The North American Regional Action Plan (NARAP) on Lindane and Other Hexachlorocyclohexane (HCH) Isomers. 2005. Available at: http://www.cec.org/files/PDF/POLLUTANTS/Lindane-NARAP-Public-Comment_en.pdf.
  6. ^ a b c d e f g h Agency for Toxic Substances and Disease Registry, U.S. Department of Health and Human Services. Toxicologic profile for alpha-, beta, gamma- and delta-hexachlorocyclohenxane. August 2005. http://www.atsdr.cdc.gov/toxprofiles/tp43.pdf
  7. ^ Lindane Voluntary Cancellation and RED Addendum Fact Sheet, US EPA, July name 2006.
  8. ^ a b c International Agency for Research on Cancer (IARC). Summaries & Evaluations: HEXACHLOROCYCLOHEXANES (Group 2B). Updated March 2, 1998. http://www.inchem.org/documents/iarc/suppl7/hexachlorocyclohexanes.html
  9. ^ a b c U.S. EPA. Evaluation of the Carcinogenic Potential of Lindane, PC. Code: 009001. 2001. http://www.lindane.com/pdf/EPA_Cancer_Assessment_of_Lindane2001.pdf
  10. ^ a b World Health Organization (WHO). Lindane in Drinking Water: Background Document for Development of WHO Guidelines for Drinking-Water Quality. 2004.
  11. ^ World Health Organization, The WHO Recommended Classification of Pesticides by Hazard, 2005.
  12. ^ a b Eliane Engeler, "UN: Treaty expanded by 9 more dangerous chemicals", Associated Press 2009-05-09
  13. ^ a b c d e f Commission for Environmental Cooperation. North American Regional Action Plan (NARAP) on lindane and other hexachlorocyclohexane (HCH) isomers. November 30, 2006. http://www.cec.org/files/PDF/POLLUTANTS/LindaneNARAP-Nov06_en.pdf
  14. ^ a b c U.S. Environmental Protection Agency (EPA). Lindane Reregistration Eligibility Decision (RED). 2002. http://www.epa.gov/espp/effects/lindane/attach-1.pdf
  15. ^ a b c d U.S. EPA. Addendum to the 2002 Lindane Reregistration Eligibility Decision (RED). July 2006. http://www.epa.gov/oppsrrd1/REDs/lindane_red_addendum.pdf
  16. ^ a b c Food and Drug Administration. Lindane Assessment Memorandum. Posted 2003. http://www.fda.gov/cder/drug/infopage/lindane/lindanememoassessment.pdf.
  17. ^ National Pesticide Information Retrieval System. Available at: http://ppis.ceris.purdue.edu/npublic.htm.
  18. ^ McCarthy JS, Kemp DJ, Walton SF, Currie BJ (2004). "Scabies: more than just an irritation". Postgrad Med J. 80 (945): 382–7. doi:10.1136/pgmj.2003.014563. PMID 15254301.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  19. ^ Thomas DR, McCarroll L, Roberts R; et al. (2006). "Surveillance of insecticide resistance in head lice using biochemical and molecular methods". Arch. Dis. Child. 91 (9): 777–8. doi:10.1136/adc.2005.091280. PMID 16774979. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  20. ^ a b FDA Public Health Advisory: Safety of Topical Lindane Products for the Treatment of Scabies and Lice. Availasble at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm110845.htm
  21. ^ Witkowski JA, Parish LC. Lindane-resistant scabies. J Am Acad Dermatol. 1992 Oct;27(4):648..
  22. ^ Parish LC, Witkowski JA, Kucirka SA. Lindane resistance and pediculosis capitis. Int J Dermatol. 1983 Dec;22(10):572-4.
  23. ^ Elston DM. Nit picking. J AM ACAD DERMATOL. 2005; 35:164.
  24. ^ McCarthy JS, Kemp DJ, Walton SF, et al. Scabies: more than just an irritation. Postgrad Med J. 2004;80:382–387.
  25. ^ Roberts RJ. Clinical practice. Head lice. N Engl J Med. 2002;346(21):1645–50.
  26. ^ Johnston G, Sladden M. Scabies: diagnosis and treatment. British Med J. 2005;331:619–622.
  27. ^ Chosidow O. Scabies and pediculosis. Lancet. 2000;355:819–826.
  28. ^ Currie BJ, Harumal P, McKinnon M, et al. First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clin Infect Dis. 2004;39:e8–e12.
  29. ^ Thomas DR, McCarroll L, Roberts R, et al. Surveillance of insecticide resistance in head lice using biochemical and molecular methods. Arch Dis Child. 2006;91:777–778.
  30. ^ Pollack RJ, Kiszewski A, Armstrong P, et al. Differential permethrin susceptibility of head lice sampled in the United States and Borneo. Arch Pediatr Adolesc Med. 1999;153:969–973.
  31. ^ Downs AM. Managing head lice in an era of increasing resistance to insecticides. Am J Clin Dermatol. 2004;5(3):169–177.
  32. ^ Kwon DH, Yoon KS, Strycharz JP, Clark JM, Lee SH. Determination of permethrin resistance allele frequency of human head louse populations by quantitative sequencing. J Med Entomol. 2008 Sep;45(5):912-20.
  33. ^ Clark JM. Determination, mechanism and monitoring of knockdown resistance in permethrin-resistant human head lice, Pediculus humanus capitis. Journal of Asia-Pacific Entomology 12 (2009) 1–7.
  34. ^ Burkhart CG, Burkhart CN.Safety and efficacy of pediculicides for head lice. Expert Opin Drug Saf. 2006 Jan;5(1):169-79.
  35. ^ Dodd CS.Withdrawn: Interventions for treating head lice. Cochrane Database Syst Rev. 2007 Jul 18;(4):CD001165.
  36. ^ Sciele Pharma Completes Acquisition of Alliant Pharmaceuticals. Press Release; June 12, 2007. http://phx.corporate-ir.net/phoenix.zhtml?c=120763&p=irol-newsArticle&ID=1014610&highlight
  37. ^ Warning Letter from the U.S. Food and Drug Administration to Morton Grove. (undated.)
  38. ^ Corrective information on lindane shampoo available at: http://www.lindane4lice.com/
  39. ^ http://www.legislature.mi.gov/(S(qmov3e45chfz0w55ymrrcl45))/mileg.aspx?page=getObject&objectName=2009-HB-4402
  40. ^ a b c d e Humphreys EH, Janssen S, Heil A, Hiatt P, Solomon G, Miller MD (2008). "Outcomes of the California ban on pharmaceutical lindane: clinical and ecologic impacts" (PDF). Environ. Health Perspect. 116 (3): 297–302. doi:10.1289/ehp.10668. PMC 2265033. PMID 18335094. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  41. ^ a b Persistent Organic Pollutant Review Committee (POPRC). Draft risk management evaluation for lindane. May, 2007. http://www.pops.int/documents/meetings/poprc/drprofile/drme/DraftRME_Lindane.pdf
  42. ^ "Unintentional topical lindane ingestions--United States, 1998-2003". MMWR Morb. Mortal. Wkly. Rep. 54 (21): 533–5. 2005. PMID 15931156..
  43. ^ U.S. FDA Centers for Drug Evaluation and Research. Lindane lotion and lindane shampoo questions and answers. Updated April 15, 2003. http://www.fda.gov/cder/drug/infopage/lindane/lindaneQA.htm
  44. ^ Alvarez-Pedrerol M, Ribas-Fitó N, Torrent M; et al. (2008). "Thyroid disruption at birth due to prenatal exposure to beta-hexachlorocyclohexane". Environ Int. 34: 737. doi:10.1016/j.envint.2007.12.001. PMID 18207242. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  45. ^ IARC. Lindane (CAS No. 58-89-9) and Other Hexachlorocyclohexane Isomers. Report on carcinogens. 11th report. Available at: http://ntp.niehs.nih.gov/ntp/roc/eleventh/profiles/s102lind.pdf.
  46. ^ Medication Guide Lindane Lotion USP, 1%. Updated March 28, 2003. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM133687.pdf.
  47. ^ Medication Guide Lindane Shampoo USP, 1%. Updated March 28, 2003. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM133688.pdf.
  48. ^ Andrews EB, Joseph MC, Magenheim MJ, et al. Postmarketing surveillance study permethrin crème rinse. Am J Public Health. 1992;82(6):857-861.
  49. ^ a b U.S. FDA. Lindane Post Marketing Safety Review. Posted 2003. http://www.fda.gov/cder/drug/infopage/lindane/lindaneaeredacted.pdf.
  50. ^ a b Lindane lotion, USP, 1% prescribing information. Updated March 28, 2003. http://www.fda.gov/cder/foi/label/2003/006309lotionlbl.pdf
  51. ^ a b Lindane shampoo, USP, 1% prescribing information. Updated March 28, 2003. http://www.fda.gov/cder/foi/label/2003/006309shampoolbl.pdf.
  52. ^ http://www.fda.gov/cder/drug/infopage/lindane/default.htm
  53. ^ a b U.S. EPA. Assessment of lindane and other hexachlorocyclohexane isomers. February 8, 2006
  54. ^ a b United Nations Environment Programme. POPRC of the Stockholm Convention. Draft risk profile: Lindane. July 2006.
  55. ^ Life after Lindane in California: Water Concentrations, Poison Control Calls Drop Following Ban, Environmental Health Perspectives, Volume 116, Number 3, March 2008.
  56. ^ a b c International HCH & Pesticides Association. The legacy of lindane HCH isomer production. 2006. http://www.ihpa.info/docs/library/Lindane%20Main%20Report%20DEF20JAN06.pdf
  57. ^ US CDC. Third National Report on Human Exposure to Environmental Chemicals. 2005. Available at: http://www.cdc.gov/ExposureReport/pdf/thirdreport.pdf.
  58. ^ Kolpin DW, Furlong ET, Meyer MT, et al. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999–2000: A national reconnaissance. Environ Sci Technol. 2002;36(6):1202–1211.
  59. ^ a b c d e U.S. EPA. Announcem[ent of completion of EPA’s review of existing drinking water standards. Federal Register. 68(138): July 18, 2003.
  60. ^ California Public Health Goal for Lindane in Drinking Water. Available at: http://oehha.ca.gov/water/phg/pdf/lindan_f.pdf.
  61. ^ IPEN. Lindane: Agricultural and pharmaceutical alternatives to lindane. Available at: http://www.akaction.org/REPORTS/Alternatives%20to%20Lindane%20Report%204-29-09.pdf
  62. ^ a b Report of the Conference of the Parties of the Stockholm Convention on Persistent Organic Pollutants on the work of its fourth meeting. Convention on Persistent Organic Pollutants. Fourth meeting, Geneva, 4–8 May 2009. http://chm.pops.int/Portals/0/Repository/COP4/UNEP-POPS-COP.4-38.English.pdf.
  63. ^ Persistent Organic Pollutants Review Committee http://www.pops.int/documents/meetings/poprc/chemreview.htm
  64. ^ Pesticide Action Network map of Lindane bans and restrictions http://www.panna.org/campaigns/docsLindane/lindaneBannedMap.pdf
  65. ^ "Pollu beetle menace in pepper". The Hindu. Retrieved 2008-05-29. {{cite web}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  66. ^ Shaibu, Inalegwu (14 May 2008). "Nigeria: NAFDAC Bans 30 Agrochemical Products". Retrieved 2008-05-29.
  67. ^ Bill Summary - A06802
  68. ^ a b Critics of drugs in for bad medicine, Laura Berman, The Detroit News, March 2, 2008.
  69. ^ HB-4569, As Passed House, May 15, 2008 Michigan Legislature website.
  70. ^ Morton Grove Pharmaceuticals, Inc. v. The National Pediculosis Association, et al., No. 06 C 3815 (N.D. Ill. June 18, 2007) (Bucklo, J.)
  71. ^ The Ecology Center's Clarification of Statements Regarding Lindane, Michigan Ecology Center, accessed March 3, 2008.
  72. ^ Ecology Center's lindane suit settled, Art Aisner, Ann Arbor News, March 15, 2008.
  73. ^ Morton Grove Pharmaceuticals, Inc. v. The National Pediculosis Association, No. 08-C-1384 (N.D. Ill.)

External links

Government and organizations

News stories and opinion articles

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lindane&oldid=336841782"